RecruitingNot Applicable

Esketamine Combined Pulsed Radiofrequency for Acute/Subacute Zoster-associated Trigeminal Neuralgia

China174 participantsStarted 2025-04-01

Plain-language summary

To assess the 1-month effects and safety of esketamine combined PRF and standardized treatment to relieve pain in patients with acute/subacute zoster-related trigeminal neuralgia(ZRTN).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age \>18 years;
✓. History of HZ within the last three months;
✓. Lesions located in the trigeminal nerve or its branches innervated regions；
✓. Numeric Rating Scale (NRS) pain score≥4 (NRS, 0 = no pain, 10= worst possible pain) with pharmacotherapy;
✓. Planned to perform CT-guided PRF treatment of the Gasserian ganglion .

Exclusion criteria

✕. Obstructive sleep apnoea syndrome;
✕. Those who receive other invasive treatments, such as spinal cord stimulation;
✕. A history of systemic immune diseases, organ transplantation, or cancers;
✕. A history of severe cardiopulmonary, hepatic or renal dysfunction;
✕. A history of schizophrenia, epilepsy, or myasthenia gravis, delirium;
✕. Comorbid hyperthyroidism or phaeochromocytoma;
✕. Recent history of drug abuse;
✕. Having contraindications to esketamine;

What they're measuring

the NRS score at 1 month after treatment.

Timeframe: 1-month period

Trial details

NCT IDNCT06890897

SponsorBeijing Tiantan Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06-30

Contact for this trial

Fang Luo, M.D.

+86 13611326978 13611326978@163.com

View on ClinicalTrials.gov More Zoster; Herpes, Trigeminal Neuralgia (Etiology) trials